US equities |
MU $1,097.39 ▲+3.03% NVDA $230.86 ▲+1.09% SNDK $1,787.69 ▲+2.75% INTC $120.00 ▼-0.19% AAPL $330.32 ▼-0.81% GOOGL $338.24 ▼-1.70% TSLA $354.11 ▼-0.20% AMD $615.73 ▲+0.65%
FinancialContent

Articles published by Amprion

News headline image
Amprion and Prema Cognition Partner to Advance Multimodal Assessment of Neurodegenerative Disease
From Amprion
Via Business Wire
News headline image
Amprion Launches SAAmplify®-αSYN Plus: The First & Only Commercially Available CSF Test to Detect Alpha-Synuclein Profile for Multiple System Atrophy
From Amprion
Via Business Wire
News headline image
Amprion Partners with MLM Medical Labs to Expand Alpha-Synuclein SAA Testing in Europe
From Amprion
Via Business Wire
News headline image
Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease
From Amprion
Via Business Wire
News headline image
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
From Amprion
Via Business Wire
News headline image
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
From Amprion
Via Business Wire
News headline image
Amprion Announces Landmark Study in The Lancet Neurology
From Amprion
Via Business Wire
News headline image
Amprion Honored to Win the 2024 BioTech Breakthrough Award ‘Clinical Diagnostics Solution of the Year’
From Amprion
Via Business Wire
News headline image
Amprion Announces Initial Close of a $15M Financing to Commercialize Groundbreaking Neurologic Diagnostics
From Amprion
Via Business Wire
News headline image
FDA Issues Letter of Support for α-Synuclein Seed Amplification Assay – The Core Technology Used in Amprion’s First Commercial Test
From Amprion
Via Business Wire
News headline image
Amprion Unveils Next-Generation SAAmplify™ Biomarker Panels to Aid in Diagnosis of Neurodegenerative Disorders at AAIC 2024
From Amprion
Via Business Wire